author-photo

C. Gisselbrecht

Institut Gustave Roussy

79

Papers

1647

Citations

Citation Trend

Filter By

Papers (66) Sort By

Journal Conference Others

Autologous Stem Cell Transplantation in Intermediate and High Grade Lymphoma

2020
- C. Gisselbrecht
- B. Coiffier
Show All
- Source
- Cite
- Save
Citations (0)
FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION ‐ FINAL RESULTS OF THE AATT STUDY

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (32)
A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05–1T trial

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (23)
MYC+ Diffuse Large B Cell Lymphomas (DLBCL) Treated in Randomized Prospective Salvage Therapy, RICE or RDHAP Followed by BEAM Plus Autologous Stem Cell Transplantation (ASCT). A BioCORAL Report

2011 Blood
Show All
- Source
- Cite
- Save
Citations (1)
R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma

2011 Blood
Show All
- Source
- Cite
- Save
Citations (26)
R-CHOP VERSUS R-FC FOLLOWED BY MAINTENANCE WITH RITUXIMAB OR IFN : FIRST RESULTS OF A RANDOMIZED TRIAL FOR ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA

2011 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy.

2010 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (33)
High dose therapy and autologous stem cell transplantation in first relapse for dlbcl still improves progression free survival in the rituximab era. a retrospective analysis of the ebmt-lwp

2010 Haematologica-the Hematology Journal
Show All
- Source
- Cite
- Save
Citations (0)
Rituximab plus gemcitabine and oxaliplatine (R-GemOx) in refractory/relapsed patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for high-dose therapy (HDT): A GELA study.

2010 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)